Publications
View AllSafety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (...
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; Clinic...
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab tha...
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks...
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chro...
Affiliated Researchers
Institution Info
- Type
- facility
- Country
- US
- Publications
- 43
- Citations
- 140,343
External Links
Identifiers
- ROR
- https://ror.org/05m5b8x20